Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar.
JSR Life Sciences is set to expand European gene-to-GMP biologics manufacturing facilities of its affiliate companies KBI Biopharma and Selexis in Geneva, Switzerland.
Vifor Pharma has entered into a licence agreement with Cara Therapeutics to commercialise Korsuva (difelikefalin) to treat chronic kidney disease-associated pruritus (CKD-aP) in the US.
The World Bank has sanctioned a package of $12bn for developing nations towards the purchase and distribution of Covid-19 vaccines, treatments, and tests.
European Commission (EC) has approved an advance purchase agreement under which Janssen Pharmaceutical Companies will supply up to 400 million doses of its Covid-19 vaccine candidate.
Johnson & Johnson (J&J) company Janssen Pharmaceuticals has partnered with injectable contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (GRAM) to produce its SARS-CoV-2 vaccine candidate.
Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted Covid-19 vaccine, beginning in 2021.
Vifor Pharma has announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding.
British drugmaker GlaxoSmithKline (GSK) and French pharmaceutical firm Sanofi have entered into an advanced purchase agreement with the European Commission (EC) to supply up to 300 million doses of adjuvanted Covid-19 vaccine.
Santen Pharmaceutical and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc. ("Eyevance").
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.